Evidence map›Paper›PMID 41028776›Full record

Trial reportScientific reports2025

Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer.

Yasunari Sakamoto, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Nobuyoshi Hiraoka, Tomoki Shirota, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Hiroshi Imaoka and 15 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yasunari SakamotoDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. yasakamo@ihwg.jp.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Junki MizusawaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Nobuyoshi HiraokaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Tomoki ShirotaDepartment of Surgery, Suwa Red Cross Hospital, Suwa, Nagano, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Hiroshi ImaokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Masato OzakaHepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Tokyo, Japan.
Hironori YamaguchiDepartment of Clinical Oncology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Nobumasa MizunoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Akio KatanumaCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Yasushi KojimaDepartment of Gastroenterology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Kunihito GotohDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Keiya OkamuraDepartment of Bilio-Pancreatology, Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Kazuya SugimoriGastroenterological Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University, Kanazawa, Ishikawa, Japan.
Rie SugimotoDepartment of Hepato-Biliary-Pancreatology, National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan.
Hirofumi ShirakawaDepartment of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Utsunomiya, , Tochigi, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The phase III randomized trial, JCOG1113 has demonstrated the non-inferiority of gemcitabine and S-1 (GS) therapy to gemcitabine and cisplatin (GC) therapy for advanced biliary tract cancer (BTC). However, biomarkers for favorable therapy or to predict patient prognosis remain lacking. In this study, we evaluated five candidate biomarkers potentially involved in the efficacy of cisplatin or S-1 by immunostaining tumor specimens obtained from JCOG1113 participants. The participants were randomly divided into training or test sets and classified into high- or low-expression groups based on the cutoff value calculated from the immunostaining results for each biomarker in the training set. Associations between the expression of each biomarker and the outcomes in JCOG1113 were analyzed. Among the 148 eligible participants, no interaction was observed between the treatment arms of GC or GS for any factor or biomarker. However, high excision repair cross-complementing gene 1 (ERCC1) was associated with poor overall survival (HR, 2.226; 95% CI, 1.160-4.272) and progression-free survival (HR, 1.793; 95% CI, 0.945-3.402) compared with low ERCC1 in the training set. Similar trends were observed for the test set. Our results indicate that in advanced BTC, high ERCC1 expression is a poor prognostic factor.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsDNA-Binding ProteinsEndonucleasesAgedBiomarkers, TumorCisplatinDeoxycytidineDrug CombinationsFemaleGemcitabineHumansMaleMiddle AgedOxonic AcidPrognosisBiomarkers, TumorCisplatinDeoxycytidineDNA-Binding ProteinsDrug CombinationsEndonucleasesERCC1 protein, humanGemcitabineOxonic AcidS 1 (combination)TegafurBiliary tract cancerChemotherapyERCC1Prognostic factor

Identifiers

PMID41028776
PMCPMC12485096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.